| scholarly article | Q13442814 |
| P2093 | author name string | Jian Zhang | |
| Dihua Yu | |||
| Hai Wang | |||
| Samuel W Brady | |||
| Daniel Seok | |||
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation | Q27684731 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers | Q27851710 | ||
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. | Q27851896 | ||
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas | Q28256478 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib | Q33933626 | ||
| Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors | Q34005966 | ||
| The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells | Q34234737 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers | Q34679149 | ||
| Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts | Q34694605 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications | Q35591518 | ||
| Rare cancer-specific mutations in PIK3CA show gain of function | Q35720258 | ||
| Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors | Q35779022 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation | Q36322762 | ||
| Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance | Q36489360 | ||
| Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms | Q36497469 | ||
| Cancer-specific mutations in phosphatidylinositol 3-kinase | Q36846595 | ||
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 | ||
| Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. | Q36986301 | ||
| ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization | Q37054834 | ||
| ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer | Q37153622 | ||
| Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA | Q37350385 | ||
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 | ||
| Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib | Q39700483 | ||
| Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Q39813764 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines | Q40168416 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 | ||
| Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells | Q40345016 | ||
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies | Q45246419 | ||
| Multiplexed assays for detection of mutations in PIK3CA. | Q54539805 | ||
| Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas | Q80236139 | ||
| Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation | Q83201817 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 60-70 | |
| P577 | publication date | 2013-11-18 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor | |
| P478 | volume | 13 |
| Q38745816 | Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer |
| Q38238598 | Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine. |
| Q38945477 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer |
| Q37283004 | Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. |
| Q36311216 | Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells |
| Q27711042 | Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946) |
| Q37013898 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer |
| Q38434942 | Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer |
| Q36729467 | Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients |
| Q38812867 | Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms |
| Q90749099 | Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer |
| Q48354684 | Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer |
| Q89985629 | Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis |
| Q48095126 | NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib |
| Q38259259 | PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? |
| Q38835374 | Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib |
| Q91643385 | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy |
| Q34096861 | The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells |
| Q38214802 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic |
Search more.